학술논문
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)
Document Type
article
Author
Livio Pagano; Jon Salmanton-García; Francesco Marchesi; Alessandro Busca; Paolo Corradini; Martin Hoenigl; Nikolai Klimko; Philipp Koehler; Antonio Pagliuca; Francesco Passamonti; Luisa Verga; Benjamin Víšek; Osman Ilhan; Gianpaolo Nadali; Barbora Weinbergerová; Raúl Córdoba-Mascuñano; Monia Marchetti; Graham P. Collins; Francesca Farina; Chiara Cattaneo; Alba Cabirta; Maria Gomes-Silva; Federico Itri; Jaap van Doesum; Marie-Pierre Ledoux; Martin Čerňan; Ozren Jakšić; Rafael F. Duarte; Gabriele Magliano; Ali S. Omrani; Nicola S. Fracchiolla; Austin Kulasekararaj; Toni Valković; Christian Bjørn Poulsen; Marina Machado; Andreas Glenthøj; Igor Stoma; Zdeněk Ráčil; Klára Piukovics; Milan Navrátil; Ziad Emarah; Uluhan Sili; Johan Maertens; Ola Blennow; Rui Bergantim; Carolina García-Vidal; Lucia Prezioso; Anna Guidetti; Maria Ilaria del Principe; Marina Popova; Nick de Jonge; Irati Ormazabal-Vélez; Noemí Fernández; Iker Falces-Romero; Annarosa Cuccaro; Stef Meers; Caterina Buquicchio; Darko Antić; Murtadha Al-Khabori; Ramón García-Sanz; Monika M. Biernat; Maria Chiara Tisi; Ertan Sal; Laman Rahimli; Natasa Čolović; Martin Schönlein; Maria Calbacho; Carlo Tascini; Carolina Miranda-Castillo; Nina Khanna; Gustavo-Adolfo Méndez; Verena Petzer; Jan Novák; Caroline Besson; Rémy Duléry; Sylvain Lamure; Marcio Nucci; Giovanni Zambrotta; Pavel Žák; Guldane Cengiz Seval; Valentina Bonuomo; Jiří Mayer; Alberto López-García; Maria Vittoria Sacchi; Stephen Booth; Fabio Ciceri; Margherita Oberti; Marco Salvini; Macarena Izuzquiza; Raquel Nunes-Rodrigues; Emanuele Ammatuna; Aleš Obr; Raoul Herbrecht; Lucía Núñez-Martín-Buitrago; Valentina Mancini; Hawraa Shwaylia; Mariarita Sciumè; Jenna Essame; Marietta Nygaard; Josip Batinić; Yung Gonzaga; Isabel Regalado-Artamendi; Linda Katharina Karlsson; Maryia Shapetska; Michaela Hanakova; Shaimaa El-Ashwah; Zita Borbényi; Gökçe Melis Çolak; Anna Nordlander; Giulia Dragonetti; Alessio Maria Edoardo Maraglino; Amelia Rinaldi; Cristina De Ramón-Sánchez; Oliver A. Cornely; EPICOVIDEHA working group
Source
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-15 (2021)
Subject
Language
English
ISSN
1756-8722
Abstract
Abstract Background Patients with hematological malignancies (HM) are at high risk of mortality from SARS-CoV-2 disease 2019 (COVID-19). A better understanding of risk factors for adverse outcomes may improve clinical management in these patients. We therefore studied baseline characteristics of HM patients developing COVID-19 and analyzed predictors of mortality. Methods The survey was supported by the Scientific Working Group Infection in Hematology of the European Hematology Association (EHA). Eligible for the analysis were adult patients with HM and laboratory-confirmed COVID-19 observed between March and December 2020. Results The study sample includes 3801 cases, represented by lymphoproliferative (mainly non-Hodgkin lymphoma n = 1084, myeloma n = 684 and chronic lymphoid leukemia n = 474) and myeloproliferative malignancies (mainly acute myeloid leukemia n = 497 and myelodysplastic syndromes n = 279). Severe/critical COVID-19 was observed in 63.8% of patients (n = 2425). Overall, 2778 (73.1%) of the patients were hospitalized, 689 (18.1%) of whom were admitted to intensive care units (ICUs). Overall, 1185 patients (31.2%) died. The primary cause of death was COVID-19 in 688 patients (58.1%), HM in 173 patients (14.6%), and a combination of both COVID-19 and progressing HM in 155 patients (13.1%). Highest mortality was observed in acute myeloid leukemia (199/497, 40%) and myelodysplastic syndromes (118/279, 42.3%). The mortality rate significantly decreased between the first COVID-19 wave (March–May 2020) and the second wave (October–December 2020) (581/1427, 40.7% vs. 439/1773, 24.8%, p value